Anticancer agent comprising Anti-pd-1 antibody or Anti-pd-l1 antibody

an anticancer agent and anti-pd-1 technology, applied in the field of anticancer agents, can solve the problems of inability to achieve effective anticancer effects, inability to produce effective anticancer effects, and inability to respond to inkt cells greatly, so as to achieve greater production and increase the effect of production

Inactive Publication Date: 2010-04-08
ANTICANCER AGENT COMPRISING ANTI PD 1 ANTIBODY OR ANTI PD L1 ANTIBODY
View PDF1 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]It is therefore an object of the present invention to provide an anticancer agent which is based on the activity of iNKT cells, featuring the recovery of iNKT cell responsiveness.

Problems solved by technology

However, iNKT cells tend to greatly decrease in responsiveness following repeated stimulation after a first stimulation with their ligands via the T cell receptor.
This iNKT cell anergy is a major obstacle in immunotherapeutic trials targeting iNKT cells.
However, since repeated stimulation of iNKT cells with α-GC induces anergy leading to a great decrease in responsiveness, it cannot achieve effective anticancer effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer agent comprising Anti-pd-1 antibody or Anti-pd-l1 antibody
  • Anticancer agent comprising Anti-pd-1 antibody or Anti-pd-l1 antibody
  • Anticancer agent comprising Anti-pd-1 antibody or Anti-pd-l1 antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of PD-1 and PD Ligands in iNKT Cells

[0034]1. Experimental Animals

[0035]Six- to eight-week-old female C56BL / 6 mice were purchased from Orient Bio. All mice were bred and maintained in specific pathogen-free conditions.

[0036]2. Reagents and Antibodies

[0037]α-GC was dissolved in PBS containing 0.5% Tween 20. Hybridoma clones producing antibodies to mouse PD-1 (RMP1-14, rat IgG2a), PD-L1 (MIH-5, rat IgG2a), and PD-L2 (Ty25, rat IgG2a) were produced according to methods well known in the art [Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. Pardoll, K. Okumura, M. Azuma, and H. Yagita. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538-5545.; Tsushima, F., H. Iwai, N. Otsuki, M. Abe, S. Hirose, T. Yamazaki, H. Akiba, H. Yagita, Y. Takahashi, K. Omura, K. Okumura, and M. Azuma. 2003. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflamm...

example 2

Effects of PD-1, PD-L1 and PD-L2 on iNKT Cell Activation

[0041]The following in vitro and in vivo experiments were conducted to examine the effects of PD-1, PD-L1 and PD-L2 on iNKT cell activation.

[0042]1. iNKT Cell Activation In Vitro

[0043]After being prepared from naëve C57BL / 6 mice, 5×105 spelenocytes were incubated for 3 days with 100 ng / ml of α-GC in the presence of 50 μg / ml of the control rat IgG, the anti-PD-1 mAb, the anti-PD-L1 mAb, or the anti-PD-L2 mAb. Then, the supernatants were obtained and assayed for IFN-γ and IL-4 levels by ELISA.

[0044]The results are given in FIG. 2.

[0045]Compared with control IgG treatment, as is apparent from FIG. 2, anti-PD-1 mAb significantly increased the production of IFN-γ and, to a lesser extent, IL-4. Anti-PD-L1 mAb also induced greater production of IFN-γ, but anti-PD-L2 mAb did not.

[0046]2. iNKT Cell Activation in Vivo

[0047]C57BL / 6 mice was injected with 200 μg of the control rat IgG, the anti-PD-1 mAb, the anti-PD-L1 mAb or the anti-PD-L...

example 3

Effects of Blockage of PD-1 / PD-L1 Interaction on Responsiveness of Anergic iNKT Cells

[0052]The following in vitro and in vivo experiments were performed in order to examine whether the blockage of PD-1 / PD-L 1 interaction reverses iNKT cell anergy.

[0053]1. Recovery of Responsiveness of Anergic iNKT Cells in Vitro

[0054]The α-GC-induced unresponsiveness of iNKT cells was detected as early as 3 days after primary stimulation and observed to persist until 7˜30 days after α-GC stimulation. Thus, C57BL / 6 mice were injected with 2 μg of α-GC to induce iNKT cell anergy. One week and one month later, splenocytes were isolated from the mice and 5×105 cells were incubated for 3 days with 100 ng / ml of α-GC in the presence of 50 μg / ml of the control rat IgG, the anti-PD-1 mAb, the anti-PD-L1 mAb, or the anti-PD-L2 mAb. Also, splenocytes isolated from the mice were incubated for 3 days with 10 ng / ml of α-GC without mAb, and these were represented by ‘activation’. The supernatants were then assayed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1 / PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority from Korean Patent Application No.10-2008-0097236, filed Oct. 2, 2008, the entire disclosure of which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]The present invention relates, in general, to an anticancer agent and, more particularly, to an anticancer agent comprising an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to restore the responsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand.BACKGROUND OF THE INVENTION[0003]Natural killer T (NKT) cells, co-expressing a T cell receptor and NK cell markers, are essential for several aspects of immunity, such as immunomodulation and immunuopotentiation, in various immune diseases including autoimmune diseases, infectious diseases, cancer, etc. NKT cells exist at high levels in the thymus, the liver, and the bone marrow, but at low levels in the spleen,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K39/39558A61K2039/505C07K16/2818C07K16/2827C07K2317/76A61K2300/00A61P35/00A61P35/02A61P37/02A61P43/00A61K39/395
Inventor KANG, CHANG YUILCHANG, WOO SUNGKIM, JI YEON
Owner ANTICANCER AGENT COMPRISING ANTI PD 1 ANTIBODY OR ANTI PD L1 ANTIBODY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap